Factbox: Vaccines delivered under COVAX sharing scheme for poorer countries
July 1 (Reuters) – The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delivered 1.55 billion COVID-19 vaccine doses to 146 countries, GAVI data shows.
In December, COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.
The following tables list countries that have received vaccines under the scheme in alphabetic order:
AFRICA & MIDDLE EAST
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE
TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Algeria
|
3.6 million
|
December 24
|
J&J
|
44 million
|
6.0 million
|
|
Angola
|
801,000
|
December 25
|
Pfizer/BioNTech
|
33 million
|
14.8 million
|
|
Benin
|
336,000
|
November 4
|
J&J
|
12 million
|
1.1 million
|
|
Botswana
|
300,000
|
October 1
|
AstraZeneca/
Oxford
|
2.5 million
|
560,460
|
|
Burkina Faso
|
700,000
|
May 1
|
Pfizer/BioNTech
|
21 million
|
1.8 million
|
|
Cameroon
|
68,600
|
April 1
|
AstraZeneca/
Oxford
|
27 million
|
1.1 million
|
|
Cape Verde
|
200,000
|
December 7
|
Pfizer/BioNTech
|
556,000
|
324,000
|
|
Central African Republic
|
168,300
|
March 4
|
N/A
|
4.8 million
|
975,000
|
|
Chad
|
828,000
|
March 24
|
J&J
|
16 million
|
1.0 million
|
|
Comoros Islands
|
90,000
|
May 8
|
Pfizer/BioNTech
|
870,000
|
360,810
|
|
Congo
|
168,000
|
November 15
|
J&J
|
5.5 million
|
470,400
|
|
Democratic Republic of Congo
|
2.1 million
|
June 28
|
N/A
|
90 million
|
4.7 million
|
|
Djibouti
|
151,200
|
July 17
|
J&J
|
988,000
|
175,200
|
|
Egypt
|
1.5 million
|
April 7
|
Pfizer/BioNTech
|
102 million
|
30.5 million
|
|
Eswatini
|
100,620
|
October 6
|
Pfizer/BioNTech
|
1.1 million
|
429,420
|
|
Equatorial Guinea
|
60,480
|
June 1
|
Moderna
|
1.4 million
|
60,480
|
|
Ethiopia
|
13.1 million
|
February 2
|
J&J
|
115 million
|
27.5 million
|
|
Gabon
|
101,790
|
November 1
|
Pfizer/BioNTech
|
2.2 million
|
370,410
|
|
Gambia
|
100,620
|
March 3
|
Pfizer/BioNTech
|
2.4 million
|
477,420
|
|
Ghana
|
309,600
|
March 14
|
AstraZeneca/Oxford
|
31 million
|
16.6 million
|
|
Guinea
|
168,000
|
November 14
|
J&J
|
13 million
|
1.7 million
|
|
Guinea-Bissau
|
136,800
|
March 25
|
J&J
|
2.0 million
|
496,800
|
|
Iran
|
700,000
|
January 14
|
AstraZeneca/Oxford
|
84 million
|
5.7 million
|
|
Iraq
|
500,000
|
August 14
|
Pfizer/BioNTech
|
40 million
|
836,000
|
|
Ivory Coast
|
816,660
|
January 3
|
Pfizer/BioNTech
|
26 million
|
8.6 million
|
|
Jordan
|
146,400
|
June 3
|
AstraZeneca/Oxford
|
10 million
|
436,800
|
|
Kenya
|
500,000
|
May 10
|
Pfizer/BioNTech
|
54 million
|
20.3 million
|
|
Lebanon
|
613,340
|
December 22
|
N/A
|
6.8 million
|
982,940
|
|
Lesotho
|
169,070
|
November 19
|
J&J
|
2.1 million
|
644,090
|
|
Liberia
|
583,200
|
June 1
|
J&J
|
5.1 million
|
2.0 million
|
|
Libya
|
1.2 million
|
December 20
|
Pfizer/BioNTech
|
6.9 million
|
1.9 million
|
|
Madagascar
|
240,000
|
February 17
|
J&J
|
28 million
|
1.9 million
|
|
Malawi
|
277,080
|
February 26
|
AstraZeneca/Oxford
|
19 million
|
2.0 million
|
|
Mali
|
58,500
|
June 15
|
Pfizer/BioNTech
|
20 million
|
2.8 million
|
|
Mauritania
|
57,330
|
June 2
|
Pfizer/BioNTech
|
4.6 million
|
2.2 million
|
|
Mauritius
|
203,580
|
January 12
|
Pfizer/BioNTech
|
1.3 million
|
387,270
|
|
Morocco
|
1.5 million
|
January 29
|
Pfizer/BioNTech
|
37 million
|
2.7 million
|
|
Mozambique
|
1.2 million
|
February 11
|
AstraZeneca/Oxford
|
31 million
|
8.4 million
|
|
Namibia
|
19,890
|
February 18
|
Pfizer/BioNTech
|
2.5 million
|
512,690
|
|
Niger
|
398,000
|
February 4
|
Pfizer/BioNTech
|
24 million
|
1.6 million
|
|
Nigeria
|
2.0 million
|
February 7
|
J&J
|
206 million
|
17.2 million
|
|
Palestinian Territories
|
299,520
|
April 27
|
Pfizer/BioNTech
|
4.7 million
|
1.6 million
|
|
Rwanda
|
254,400
|
June 27
|
N/A
|
13 million
|
4.2 million
|
|
Sao Tome and Principe
|
24,000
|
March 3
|
AstraZeneca/Oxford
|
219,000
|
24,000
|
|
Senegal
|
300,000
|
March 31
|
AstraZeneca/Oxford
|
17 million
|
3.5 million
|
|
Seychelles
|
39,780
|
December 17
|
Pfizer/BioNTech
|
98,460
|
74,880
|
|
Sierra Leone
|
168,000
|
November 23
|
J&J
|
8.0 million
|
785,310
|
|
Somalia
|
286,650
|
May 25
|
Pfizer/BioNTech
|
16 million
|
1.7 million
|
|
South Africa
|
5.6 million
|
July 31
|
Pfizer/BioNTech
|
59 million
|
5.6 million
|
|
South Sudan
|
949,500
|
April 5
|
N/A
|
11 million
|
1.9 million
|
|
Sudan
|
604,800
|
February 16
|
J&J
|
44 million
|
3.9 million
|
|
Syria
|
4.0 million
|
January 26
|
J&J
|
17 million
|
5.7 million
|
|
Tanzania
|
2.6 million
|
June 9
|
J&J
|
60 million
|
7.5 million
|
|
Togo
|
633,600
|
November 25
|
J&J
|
8.3 million
|
3.0 million
|
|
Tunisia
|
599,040
|
March 31
|
N/A
|
12 million
|
5.4 million
|
|
Uganda
|
2.9 million
|
March 9
|
J&J
|
46 million
|
14.6 million
|
|
Yemen
|
100,800
|
February 24
|
AstraZeneca/Oxford
|
30 million
|
2.2 million
|
|
Zambia
|
950,350
|
June 30
|
J&J
|
18 million
|
5.4 million
|
|
Zimbabwe
|
2.6 million
|
January 19
|
N/A
|
15 million
|
3.5 million
|
EUROPE
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Albania
|
40,800
|
June 2
|
AstraZeneca/Oxford
|
2.8 million
|
120,000
|
|
Armenia
|
187,200
|
September 5
|
AstraZeneca/Oxford
|
3.0 million
|
261,200
|
|
Azerbaijan
|
84,000
|
April 4
|
AstraZeneca/Oxford
|
10 million
|
84,000
|
|
Bosnia
|
32,760
|
May 10
|
Pfizer/BioNTech
|
3.3 million
|
82,560
|
|
Georgia
|
43,200
|
March 13
|
AstraZeneca/Oxford
|
3.7 million
|
43,200
|
|
Kosovo
|
4,800
|
June 22
|
N/A
|
1.8 million
|
1.2 million
|
|
Moldova
|
100,620
|
January 27
|
Pfizer/BioNTech
|
2.6 million
|
744,620
|
|
Montenegro
|
24,000
|
March 28
|
AstraZeneca/Oxford
|
622,000
|
24,000
|
|
North Macedonia
|
250,380
|
February 7
|
Pfizer/BioNTech
|
2.1 million
|
312,780
|
|
Serbia
|
115,200
|
August 25
|
AstraZeneca/Oxford
|
6.9 million
|
292,800
|
|
Ukraine
|
1.0 million
|
January 19
|
Pfizer/BioNTech
|
44 million
|
8.8 million
|
ASIA & PACIFIC
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Afghanistan
|
2.0 million
|
February 2
|
J&J
|
39 million
|
9.0 million
|
|
Bangladesh
|
4.1 million
|
June 27
|
N/A
|
165 million
|
38.9 million
|
|
Bhutan
|
90,090
|
April 5
|
Pfizer/BioNTech
|
771,612
|
90,090
|
|
Brunei
|
24,000
|
April 2
|
AstraZeneca/Oxford
|
437,000
|
24,000
|
|
Cambodia
|
2.0 million
|
May 3
|
Pfizer/BioNTech
|
17 million
|
4.9 million
|
|
East Timor
|
100,620
|
February 12
|
Pfizer/BioNTech
|
1.3 million
|
494,040
|
|
Fiji
|
9,600
|
June 29
|
Moderna
|
896,000
|
312,080
|
|
Indonesia
|
3.5 million
|
March 5
|
Pfizer/BioNTech
|
274 million
|
52.3 million
|
|
Kiribati
|
23,400
|
June 6
|
Pfizer/BioNTech
|
119,000
|
127,400
|
|
Kyrgyzstan
|
149,760
|
February 1
|
Pfizer/BioNTech
|
6.6 million
|
800,300
|
|
Laos
|
1.7 million
|
January 26
|
Pfizer/BioNTech
|
7.3 million
|
7.6 million
|
|
Malaysia
|
559,200
|
September 17
|
AstraZeneca/Oxford
|
32 million
|
1.4 million
|
|
Maldives
|
210,600
|
January 28
|
Pfizer/BioNTech
|
541,000
|
664,540
|
|
Mongolia
|
302,400
|
June 21
|
Pfizer/BioNTech
|
3.3 million
|
1.6 million
|
|
Nauru
|
7,200
|
April 2
|
AstraZeneca/Oxford
|
10,830
|
7,200
|
|
Nepal
|
1.5 million
|
March 31
|
Pfizer/BioNTech
|
29 million
|
15.7 million
|
|
Pakistan
|
4.7 million
|
April 12
|
Pfizer/BioNTech
|
221 million
|
43.8 million
|
|
Papua New Guinea
|
302,400
|
August 6
|
J&J
|
8.9 million
|
580,400
|
|
Philippines
|
299,520
|
June 27
|
Pfizer/BioNTech
|
110 million
|
56.9 million
|
|
Samoa
|
45,630
|
May 2
|
Pfizer/BioNTech
|
198,410
|
181,630
|
|
Solomon Islands
|
52,650
|
April 11
|
N/A
|
687,000
|
262,070
|
|
Sri Lanka
|
820,000
|
December 20
|
Pfizer/BioNTech
|
22 million
|
5.0 million
|
|
Tajikistan
|
198,900
|
June 1
|
Pfizer/BioNTech
|
9.5 million
|
6.5 million
|
|
Tonga
|
7,000
|
February 15
|
N/A
|
106,000
|
67,800
|
|
Tuvalu
|
4,800
|
April 8
|
AstraZeneca/Oxford
|
11,800
|
4,800
|
|
Uzbekistan
|
2.1 million
|
March 28
|
Moderna
|
34 million
|
19.0 million
|
|
Vanuatu
|
20,400
|
April 8
|
Moderna
|
307,000
|
44,400
|
|
Vietnam
|
3.5 million
|
April 19
|
Pfizer/BioNTech
|
97 million
|
50.0 million
|
AMERICAS
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Antigua and Barbuda
|
19,200
|
November 22
|
N/A
|
98,000
|
60,000
|
|
Argentina
|
960,400
|
October 12
|
AstraZeneca/Oxford
|
45 million
|
3.9 million
|
|
Bahamas
|
57,330
|
October 18
|
Pfizer/BioNTech
|
393,000
|
124,530
|
|
Barbados
|
14,040
|
December 16
|
Pfizer/BioNTech
|
287,000
|
114,840
|
|
Belize
|
58,500
|
October 26
|
Pfizer/BioNTech
|
398,000
|
159,300
|
|
Bermuda
|
9,600
|
April 6
|
AstraZeneca/Oxford
|
64,000
|
9,600
|
|
Bolivia
|
603,720
|
April 28
|
Pfizer/BioNTech
|
12 million
|
8.6 million
|
|
Brazil
|
2.0 million
|
September 20
|
Sinovac
|
213 million
|
11.9 million
|
|
Chile
|
331,000
|
May 20
|
AstraZeneca/Oxford
|
19 million
|
489,400
|
|
Colombia
|
2.3 million
|
March 23
|
Pfizer/BioNTech
|
51 million
|
18.9 million
|
|
Costa Rica
|
200,070
|
February 28
|
Pfizer/BioNTech
|
5.1 million
|
1.6 million
|
|
Dominica
|
30,240
|
February 4
|
Moderna
|
72,000
|
133,920
|
|
Dominican Republic
|
184,800
|
August 27
|
AstraZeneca/Oxford
|
11 million
|
463,200
|
|
Ecuador
|
1.5 million
|
February 15
|
Pfizer/BioNTech
|
18 million
|
3.8 million
|
|
El Salvador
|
188,370
|
August 27
|
Pfizer/BioNTech
|
6.5 million
|
3.6 million
|
|
Grenada
|
5,040
|
June 8
|
Moderna
|
113,000
|
124,710
|
|
Guatemala
|
349,830
|
June 27
|
Pfizer/BioNTech
|
17 million
|
5.9 million
|
|
Guyana
|
28,800
|
January 14
|
J&J
|
787,000
|
291,540
|
|
Haiti
|
60,000
|
June 27
|
J&J
|
11 million
|
1.1 million
|
|
Honduras
|
153,600
|
June 30
|
Pfizer/BioNTech
|
9.9 million
|
5.7 million
|
|
Jamaica
|
398,970
|
March 21
|
Pfizer/BioNTech
|
3.0 million
|
1.9 million
|
|
Mexico
|
4.0 million
|
March 4
|
AstraZeneca/Oxford
|
129 million
|
21.3 million
|
|
Nicaragua
|
657,540
|
June 24
|
Pfizer/BioNTech
|
6.6 million
|
5.4 million
|
|
Panama
|
74,400
|
September 15
|
AstraZeneca/Oxford
|
4.3 million
|
148,800
|
|
Paraguay
|
466,830
|
January 24
|
Pfizer/BioNTech
|
7.1 million
|
1.7 million
|
|
Peru
|
1.2 million
|
November 10
|
Sinopharm
|
33 million
|
3.6 million
|
|
Saint Kitts and Nevis
|
21,600
|
April 7
|
AstraZeneca/Oxford
|
53,000
|
21,600
|
|
Saint Lucia
|
5,040
|
March 16
|
Moderna
|
184,000
|
202,470
|
|
Saint Vincent and the Grenadines
|
70,200
|
December 14
|
Pfizer/BioNTech
|
111,000
|
115,800
|
|
Suriname
|
64,800
|
December 14
|
AstraZeneca/Oxford
|
587,000
|
144,000
|
|
Trinidad and Tobago
|
84,000
|
November 27
|
Sinopharm
|
1.4 million
|
185,200
|
|
Uruguay
|
50,400
|
September 1
|
AstraZeneca/Oxford
|
3.5 million
|
148,800
|
|
Venezuela
|
4.7 million
|
March 14
|
Sinopharm
|
28 million
|
16.8 million
|
Sources: WHO, UNICEF, GAVI, releases from local authorities
Compiled by Marta Frackowiak, Antonis Pothitos, Boleslaw Lasocki, Antonis Triantafyllou, Aleksandra Jasiurska and Elizaveta Gladun Editing by Milla Nissi, William Maclean, Mark Potter, Barbara Lewis and Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.
Reuters
